Tegaserod
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Heartburn
Conditions
Heartburn, Dyspepsia
Trial Timeline
Apr 1, 2005 → Sep 1, 2006
NCT ID
NCT00171457About Tegaserod
Tegaserod is a phase 3 stage product being developed by Novartis for Heartburn. The current trial status is completed. This product is registered under clinical trial identifier NCT00171457. Target conditions include Heartburn, Dyspepsia.
What happened to similar drugs?
7 of 14 similar drugs in Heartburn were approved
Approved (7) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00511771 | Pre-clinical | Completed |
| NCT00414024 | Phase 3 | Terminated |
| NCT00390975 | Approved | Terminated |
| NCT00399659 | Phase 3 | Terminated |
| NCT00365820 | Phase 2/3 | Terminated |
| NCT00348634 | Approved | Terminated |
| NCT00171457 | Phase 3 | Completed |
| NCT00171470 | Phase 3 | Completed |
| NCT00139568 | Phase 3 | Completed |
| NCT00563758 | Pre-clinical | Terminated |
| NCT00563615 | Pre-clinical | UNKNOWN |
| NCT00171431 | Phase 3 | Terminated |
| NCT00232037 | Phase 3 | Completed |
| NCT00232102 | Phase 3 | Completed |
| NCT00232089 | Phase 3 | Completed |
| NCT00142974 | Phase 2 | Terminated |
| NCT00142987 | Approved | Completed |
| NCT00149877 | Approved | Completed |
| NCT00141089 | Phase 3 | Completed |
| NCT00171483 | Phase 3 | Completed |
Competing Products
20 competing products in Heartburn